Abbott received marketing authorization from the European Commission for the use of Humira as a treatment for severe Crohn’s disease. Humira is the first self-administered biologic for the treatment of Crohn’s disease, offering a convenient treatment option that can help patients control of their disease. This is the fourth indication for Humira in the U.S. and the EU. Crohn’s disease is a chronic, inflammatory disease of the gastrointestinal (GI) tract that affects more tha...